Clinical effect and safety study of thiotepa combined with interleukin-2 in the treatment of malignant pleural and peritoneal effusions
塞替派联合白介素-2治疗恶性胸腹腔积液的临床效果及安全性研究

摘要

目的 研究塞替派联合白介素-2治疗恶性胸腹腔积液的临床效果及安全性。方法 纳入我院2024年9月至2026年1月期间肿瘤血液内科住院治疗的恶性胸腹腔积液患者60例，随机数字表法分为研究组、对照组，各30例。对照组接受白介素-2治疗，研究组接受塞替派联合白介素-2治疗，连续治疗2个疗程。对比两组患者疗效、生活质量改善率及安全性。结果 治疗结束后4周，研究组疾病控制率（DCR）高于对照组，差异有统计学意义（P<0.05）；治疗后研究组生活质量改善率高于对照组，差异有统计学意义（P<0.05）；治疗期间，组间不良反应发生率对比无统计学意义（P>0.05）。结论 塞替派联合白介素-2治疗恶性胸腹腔积液的临床效果及安全性理想，能够有效促进患者生活质量的改善。

Abstract

Objective To investigate the clinical efficacy and safety of thiotepa combined with interleukin-2 in the treatment of malignant pleural and peritoneal effusions.
Methods A total of 60 patients with malignant pleural and peritoneal effusion who were hospitalized in the Department of Oncology and Hematology of our hospital from September 2024 to January 2026 were included and divided into a study group and a control group by random number table method, with 30 cases in each group. The control group received interleukin-2 treatment, while the study group received thiotepa combined with interleukin-2 treatment for two consecutive courses. The therapeutic effects, improvement rates of quality of life and safety of the two groups of patients were compared.
Results Four weeks after the treatment, the disease control rate (DCR) of the study group was higher than that of the control group, and the difference was statistically significant (P < 0.05); after the treatment, the improvement rate of quality of life in the study group was higher than that in the control group, and the difference was statistically significant (P < 0.05); during the treatment period, there was no statistically significant difference in the incidence of adverse reactions between the two groups (P > 0.05).
Conclusion   The clinical efficacy and safety of thiotepa combined with interleukin-2 in the treatment of malignant pleural and peritoneal effusions are ideal, and it can effectively promote the improvement of patients’ quality of life.